Skip to main content

Mesenchymal Stem Cells for Cardiac Repair

The Clinical Perspective

  • Living reference work entry
  • First Online:
Handbook of Stem Cell Therapy

Abstract

Cardiovascular diseases (CVDs), particularly acute and chronic ischemic heart disease (IHD), are the primary cause of morbidity and mortality worldwide. The contemporary pharmacological and invasive revascularization strategies, i.e., percutaneous coronary angiography (PCA) and coronary artery bypass grafting (CABG), reduce mortality and could only provide symptomatic relief. Cell-based therapy has emerged as a novel breakthrough strategy to ensure angiomyogenic repair of the ischemically damaged heart via the generation of neomyocytes and biological bypassing to restore regional blood flow. In this regard, bone marrow (BM)-derived mesenchymal stem cells (MSCs) have shown promise and progressed to advanced phases of clinical assessment. MSCs are one of the well-studied and characterized cell types in vitro and various small experimental animal models and during the translational animal models for safety and reparability. They are currently the most used cells for cell-based cardiovascular therapy with excellent safety profiles, immunomodulatory properties, paracrine action, and differentiation potential. With overwhelming success, researchers have advanced their efforts to bring MSCs a step closer to their eventual routine use in the clinics. This chapter summarizes the advancement of MSCs from in vitro characterization to the clinical phase and discusses their future perspective.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

Abbreviations

6-MWT:

Six-minute walk test

AMI:

Acute myocardial infarction

Ang-1:

Angiopoietin-1

BM:

Bone marrow

Brdu:

5-Bromodeoxyuridine

CFU-F:

Colony-forming units-fibroblastic

CVDs:

Cardiovascular diseases

eGFP:

Enhanced green fluorescent protein

FGF:

Fibroblast growth factor

GLP-1:

Glucagon-like peptide-1

Glut:

Glucose transporter

HSCs:

Hematopoietic stem cells

IGF-1:

Insulin-like growth factor-1

IHD:

Ischemic heart disease

ISCT:

International Society for Cell Therapy

LAD:

Left anterior descending

Lin-:

Lineage negative

LV:

Left ventricle

LVEF:

Left ventricular ejection fraction

MDCT:

Multi-detector computed tomography

MHC:

Major histocompatibility complex

miR:

MicroRNA

MSCs:

Mesenchymal stem cells

M-SPECT:

Myocardial single-photon emission tomography

NPY:

Neuropeptide Y

RBCs:

Red blood cells

SAE:

Serious adverse events

TGF-b:

Transforming growth factor-b

TUNEL:

Terminal deoxynucleotidyl transferase dUTP nick-end labeling

VEGF:

Vascular endothelial growth factor

WNT:

Homologous of wingless and Int-1

References

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Khawaja Husnain Haider .

Editor information

Editors and Affiliations

Section Editor information

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Singapore Pte Ltd.

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Al-Khani, A.M., Khalifa, M.A., Haider, K.H. (2022). Mesenchymal Stem Cells for Cardiac Repair. In: Haider, K.H. (eds) Handbook of Stem Cell Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-16-6016-0_11-1

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-6016-0_11-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-6016-0

  • Online ISBN: 978-981-16-6016-0

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics